WSGR logoWSGR logo
Mengmeng Zhang
Associate
Patents and Innovations
Boston

D617-598-7814

Download vCard
Open PDF

Dr. Mengmeng Zhang is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her technical expertise spans across a variety of fields, including immuno-oncology, biochemistry, molecular biology, chemical biology, and pharmacogenetics.

Prior to joining the firm, Mengmeng was a research fellow at the Wyss Institute of Harvard University, where she developed DNA-based diagnostic tools for circulating tumor DNA detection and co-founded a start-up company for cancer diagnosis using liquid biopsy. Before joining the Wyss Institute, she was a postdoctoral fellow in Dr. Randy King's laboratory at Harvard Medical School. In this role, she worked on developing imaging-based small molecule inhibitor screening methods for anaphase-promoting complex and studied mechanisms of mitotic exit.

Mengmeng earned her Ph.D. degree in Biochemistry from the University of Texas at Austin. During her doctoral studies, she conducted research on the mechanisms and structures of several key phosphatases involved in the post-translational modification of RNA polymerase II. She also worked on identifying small molecule inhibitors for one of the phosphatases that is involved in neuronal gene silencing. While attending graduate school, she conducted research on genetically manipulating immune cells in the tumor microenvironment for cancer therapy, focusing on macrophages.

Experience

Dr. Mengmeng Zhang is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her technical expertise spans across a variety of fields, including immuno-oncology, biochemistry, molecular biology, chemical biology, and pharmacogenetics.

Prior to joining the firm, Mengmeng was a research fellow at the Wyss Institute of Harvard University, where she developed DNA-based diagnostic tools for circulating tumor DNA detection and co-founded a start-up company for cancer diagnosis using liquid biopsy. Before joining the Wyss Institute, she was a postdoctoral fellow in Dr. Randy King's laboratory at Harvard Medical School. In this role, she worked on developing imaging-based small molecule inhibitor screening methods for anaphase-promoting complex and studied mechanisms of mitotic exit.

Mengmeng earned her Ph.D. degree in Biochemistry from the University of Texas at Austin. During her doctoral studies, she conducted research on the mechanisms and structures of several key phosphatases involved in the post-translational modification of RNA polymerase II. She also worked on identifying small molecule inhibitors for one of the phosphatases that is involved in neuronal gene silencing. While attending graduate school, she conducted research on genetically manipulating immune cells in the tumor microenvironment for cancer therapy, focusing on macrophages.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Novo Holdings and F-Prime Capital on AvenCell’s $112 Million Series B
On October 22, 2024, AvenCell Therapeutics, a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, announced that it has raised $112 million in Series B financing. The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences. Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises TCR2 Therapeutics on IP Matters Related to $124 Million Public Offering
On July 28, 2020, TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $15.50 per share. TCR2 also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the company, are expected to be $124 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by TCR2. The offering is expected to close on or about July 31, 2020, subject to customary closing conditions. TCR2 intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital, and general corporate purposes.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.